Table 3.
The frequency of grade 1–2 and grade 3–4 fluoropyrimidines-related adverse events in patients with TYMS genotypes that predict increased and decreased TS expression.
| Adverse events | TYMS genotypes that predict increased TS expression (N = 55) | TYMS genotypes that predict decreased TS expression (N = 71) | ||
|---|---|---|---|---|
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |
| Hematological | N (%) | N (%) | N (%) | N (%) |
| Neutropenia | 16 (29) | 3 (5) | 21 (30) | 4 (6) |
| Anemia | 10 (18) | 0 (0) | 16 (23) | 0 (0) |
| Thrombocytopenia | 4 (7) | 0 (0) | 6 (8) | 0 (0) |
| Neutropenic fever | 0 (0) | 0 (0) | 0 (0) | |
| Non-hematological | N (%) | N (%) | N (%) | N (%) |
| Mucositis | 4 (7) | 3 (5) | 4 (6) | 3 (4) |
| Nausea | 17 (31) | 2 (4) | 23 (32) | 2 (3) |
| Vomiting | 3 (5) | 2 (4) | 5 (7) | 1 (1) |
| Diarrhea | 4 (7) | 9 (16) | 7 (13) | 11 (15) |
| Neurotoxicity | 3 (5) | 0 (0) | 3 (4) | 4 (6) |
| Skin toxicity | 3 (5) | 3 (5) | 1 (1) | 8 (11) |
| Fatigue | 30 (55) | 2 (4) | 27 (38) | 5 (7) |
| Vasospasm | 0 (0) | 1 (2) | 0 (0) | 4 (6) |